PMID- 24666488
OWN - NLM
STAT- MEDLINE
DCOM- 20150219
LR  - 20140326
IS  - 0253-2727 (Print)
IS  - 0253-2727 (Linking)
VI  - 35
IP  - 3
DP  - 2014 Mar
TI  - [Fludarabine-based increased-intensity conditioning regimen for allogeneic 
      hematopoietic stem cell transplantation in acquired severe aplastic anemia].
PG  - 221-4
LID - 10.3760/cma.j.issn.0253-2727.2014.03.009 [doi]
AB  - OBJECTIVE: To observe the effects of increased-intensity conditioning regimen 
      with FBCA (Fludarabine, Busulfan, Cyclophosphamide, and Antithymocyte globulin) 
      for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acquired 
      severe aplastic anemia (SAA). METHODS: From January 2000 to June 2011, twenty-two 
      patients (male 12, female 10) with SAA underwent allo-HSCT with FBCA conditioning 
      regimen which consisted of fludarabine (30 mg.m(-)(2).d(-)(1)x5 d), busulfan (3 mg/kgx2 
      d), cyclophosphamide (60 mg.kg(-)(1).d(-)(1)x2 d) and ATG (2.5 mg.kg(-)(1).d(-)(1)x5 d). GVHD 
      prophylaxis was performed by cyclosporine and short-term course methotrexate. 
      Nine patients received mobilized peripheral blood stem cells transplantation and 
      13 patients underwent mobilized peripheral blood combined with bone marrow stem 
      cells. Fourteen cases were human leukocyte antigen (HLA)-matched related donors, 
      while the other 8 cases were HLA-haploidentical transplantation. Engraftment was 
      documented by short tandem repeats with polymerase chain reaction (STR-PCR) on 
      approximately day + 30, + 90, + 180, + 1 year and + 2 year, respectively. 
      Long-term survival and transplantation-related complications were analyzed. 
      RESULTS: All patients obtained prompt and sustained hematopoietic reconstitution. 
      Median time for neutrophil and PLT engraftment was 15 (range: 11-22) days and 16 
      (range: 12-27) days, respectively. All patients were full donor chimerism 
      identified by STR-PCR. 2 of the total 22 cases (9.1%) had grade I-III acute GVHD 
      and 3 (15.8%) was chronic GVHD. Three patients (13.6%) died of transplantation 
      related mortality and the other 19 cases were disease-free survival with a median 
      time of 24 (range: 0.5-140.5) months. The causes of death were cytomegalovirus 
      pneumonia (n=1), acute GVHD (n=1) and severe pulmonary infection (n=1). 
      CONCLUSION: Increased-intensity of FBCA conditioning regimen could favor donor 
      stem cell sustained engraftment for allo-HSCT in SAA.
FAU - Sun, Can
AU  - Sun C
AD  - Department of Hematology, Zhujiang Hospital of Southern Medical University, 
      Guangzhou 510282, China.
FAU - Lin, Xia
AU  - Lin X
AD  - Department of Hematology, Zhujiang Hospital of Southern Medical University, 
      Guangzhou 510282, China.
FAU - Huang, Yuxian
AU  - Huang Y
AD  - Department of Hematology, Zhujiang Hospital of Southern Medical University, 
      Guangzhou 510282, China.
FAU - Song, Chaoyang
AU  - Song C
AD  - Department of Hematology, Zhujiang Hospital of Southern Medical University, 
      Guangzhou 510282, China.
FAU - Tao, Yuan
AU  - Tao Y
AD  - Department of Hematology, Zhujiang Hospital of Southern Medical University, 
      Guangzhou 510282, China.
FAU - Tu, Sanfang
AU  - Tu S
AD  - Department of Hematology, Zhujiang Hospital of Southern Medical University, 
      Guangzhou 510282, China.
FAU - Fang, Junyong
AU  - Fang J
AD  - Department of Hematology, Zhujiang Hospital of Southern Medical University, 
      Guangzhou 510282, China.
FAU - Chen, Tuzhen
AU  - Chen T
AD  - Department of Hematology, Zhujiang Hospital of Southern Medical University, 
      Guangzhou 510282, China.
FAU - Sun, Caixia
AU  - Sun C
AD  - Department of Hematology, Zhujiang Hospital of Southern Medical University, 
      Guangzhou 510282, China.
FAU - Wu, Bingyi
AU  - Wu B
AD  - Department of Hematology, Zhujiang Hospital of Southern Medical University, 
      Guangzhou 510282, China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Observational Study
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - FA2DM6879K (Vidarabine)
RN  - P2K93U8740 (fludarabine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anemia, Aplastic/*therapy
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Graft Survival
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Tissue Donors
MH  - Transplantation Conditioning/*methods
MH  - Transplantation, Homologous
MH  - Vidarabine/analogs & derivatives
MH  - Young Adult
EDAT- 2014/03/29 06:00
MHDA- 2015/02/20 06:00
CRDT- 2014/03/27 06:00
PHST- 2014/03/27 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2015/02/20 06:00 [medline]
AID - 10.3760/cma.j.issn.0253-2727.2014.03.009 [doi]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2014 Mar;35(3):221-4. doi: 
      10.3760/cma.j.issn.0253-2727.2014.03.009.